Revolutionizing Health: Minicircle’s Innovative Gene Therapy Approach
Imagine a method to slow down aging and enhance biological functions within just 30 seconds. Minicircle, a groundbreaking gene therapy startup, aims to deliver on this promise. As Mac Davis, the Founder and CEO, articulated during his recent appearance on the podcast hosted by Jon Bier, “We want to extend the length and quality of human life.”
Mechanism of the Treatment
Minicircle specializes in therapies utilizing the hormone follistatin. This natural protein is known to increase muscle mass, expedite recovery, and mitigate inflammation. The procedure involves a swift 30-second injection into body fat, with effects lasting up to a year.
Current Status of Treatments
Though promising, these treatments have not yet received approval in the United States. Currently, patients must seek treatment in countries like Mexico and Honduras, where Minicircle administers its gene therapy under medical supervision.
Pioneering Aging Research
The potential of follistatin extends beyond simply enhancing physical performance. Preliminary animal studies indicate it could extend lifespan by over 30%. Ongoing research suggests that follistatin may also promote lean muscle growth, reduce body fat, and enhance overall quality of life.
Mac Davis observed a profound change in his own experience, stating, “I noticed a shift in how I felt — more aware, more present. It wasn’t just physical; it was a sense of clarity, of being more connected to my body and the world around me.” This underscores a transformative vision in healthcare, focused on proactive enhancement of biological functions rather than mere symptom treatment. He adds, “Gene therapy, at its core, offers the possibility to address issues before they become problems, focusing on enhancing function rather than simply treating dysfunction.”
Attracting Support and Investment
Minicircle’s operational model diverges from typical biotech firms. Lack of conventional business education and financial backing made initial funding difficult for Davis. “I didn’t come from a family of businesspeople… We tried to do a crowdfund. We raised $400. The guy asked for it back later,” he shared.
However, fortune changed when influential figures like Sam Altman and Peter Thiel expressed interest. Altman met Davis at a hotel bar and offered financial support, which was later followed by Thiel’s investment after a compelling discussion about the science behind Minicircle’s approach.
Vision for the Future
Minicircle operates at the confluence of science, ethics, and business, learning and adapting as it grows. Davis emphasizes the importance of relationships, stating, “The cost of a bad relationship is bigger than I ever knew, and the upside of a great one is even bigger.” This nuanced understanding is vital as the company progresses toward its mission: ethically and safely enhancing human potential.
Looking Ahead: Next Steps for Minicircle
Minicircle’s upcoming therapy will focus on the hormone Klotho, known for its role in preventing undesirable calcification in arteries, kidneys, and the brain. Davis remarked, “It reduces improper calcium buildup, and that’s huge for heart health and longevity.” While this therapy is currently under evaluation abroad, the firm plans to seek FDA approval for clinical use in the U.S. by the end of the year.
In summary, Minicircle is paving the way for innovative therapies aimed at extending human life quality and longevity, marking a significant evolution in health science.
